<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525824</url>
  </required_header>
  <id_info>
    <org_study_id>D356FC00003</org_study_id>
    <nct_id>NCT00525824</nct_id>
  </id_info>
  <brief_title>12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe</brief_title>
  <acronym>GRAVITY</acronym>
  <official_title>A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or
      Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low
      Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary
      Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of &gt;20%
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in TC = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in TG = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in TC/HDL-C After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment</measure>
    <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
    <description>Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C After 6 Weeks Monotherapy</measure>
    <time_frame>Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward)</time_frame>
    <description>Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value*100</description>
  </secondary_outcome>
  <enrollment type="Actual">1743</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Atherosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin (Crestor)</intervention_name>
    <description>10mg and 20 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40mg and 80 mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical
             evidence of atherosclerosis or a Framingham 10-year CHD risk score of &gt;20

          -  Patients will need to sign an informed consent before any visit procedures can be
             performed, including procedures for the optional genetic research and biomarker
             studies.

          -  Patients must be 18 years or older and will be asked to stop taking any current
             cholesterol-lowering medications. Dietary counselling will be provided which will
             include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will
             be asked to follow

        Exclusion Criteria:

          -  Use of lipid lowering drugs and other prohibited concomitant medications. History of
             statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA
             reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history
             of hypersensitivity to any components of ezetimibe.

          -  Patients considered to be unstable by their physician after the following events:

        a myocardial infarction, recent episode of unstable angina, myocardial revascularisation
        [percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG)
        surgery or another revascularisation procedure] or a transient ischaemic attack (TIA) or
        stroke and patients awaiting a planned myocardial revascularisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christie M Ballantyne, MD FACP FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Cardiovascular Disease Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margareta Grind, MD PhD FFPM</last_name>
    <role>Study Chair</role>
    <affiliation>Medicine and Sciences AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zwinderen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <state>San Isidro Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <results_first_submitted>September 3, 2009</results_first_submitted>
  <results_first_submitted_qc>September 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2009</results_first_posted>
  <last_update_submitted>May 11, 2011</last_update_submitted>
  <last_update_submitted_qc>May 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Cressman - Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Hypercholesterolaemia</keyword>
  <keyword>Coronary Heart Disease (CHD)</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eight hundred thirty-three patients (with hypercholesterolaemia and CHD or CHD risk equivalent, atherosclerosis or a 10-year CHD risk of &gt;20%) were randomized into the study, from 111 sites located in the United States (56), Peru (13), Netherlands (12), Colombia (8), Argentina (8), Brazil (6), Chile (4) and Lithuania (4).</recruitment_details>
      <pre_assignment_details>Patients underwent screening procedures (Week –6; Visit 1), and entered a 6-week dietary lead-in period. Those who fulfilled all eligibility criteria (Week –6; Visit 1) and had qualifying lipid values at Visit 2 were randomly allocated (1:1:1:1) to 1 of 4 treatments for a period of 12 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>R10 to R10 + E10</title>
          <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="P2">
          <title>R20 to R20 + E10</title>
          <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="P3">
          <title>S40 to S40 + E10</title>
          <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="P4">
          <title>S80 to S80 + E10</title>
          <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="214">Randomized population</participants>
                <participants group_id="P2" count="214">Randomized population</participants>
                <participants group_id="P3" count="202">Randomized population</participants>
                <participants group_id="P4" count="203">Randomized population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="183"/>
                <participants group_id="P4" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment/mis-randomisation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R10 to R10 + E10</title>
          <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="B2">
          <title>R20 to R20 + E10</title>
          <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="B3">
          <title>S40 to S40 + E10</title>
          <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="B4">
          <title>S80 to S80 + E10</title>
          <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="203"/>
            <count group_id="B5" value="833"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="10.14"/>
                    <measurement group_id="B2" value="61.8" spread="9.93"/>
                    <measurement group_id="B3" value="61.9" spread="9.37"/>
                    <measurement group_id="B4" value="62.1" spread="9.17"/>
                    <measurement group_id="B5" value="62.0" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.0000"/>
                    <measurement group_id="B2" value="97.0000"/>
                    <measurement group_id="B3" value="97.0000"/>
                    <measurement group_id="B4" value="90.0000"/>
                    <measurement group_id="B5" value="375.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123.0000"/>
                    <measurement group_id="B2" value="117.0000"/>
                    <measurement group_id="B3" value="105.0000"/>
                    <measurement group_id="B4" value="113.0000"/>
                    <measurement group_id="B5" value="458.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment</title>
        <description>Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment</title>
          <description>Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.7200" spread="14.1660"/>
                    <measurement group_id="O2" value="-63.4800" spread="16.6970"/>
                    <measurement group_id="O3" value="-55.2200" spread="15.7500"/>
                    <measurement group_id="O4" value="-57.4200" spread="20.4660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment</title>
        <description>Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment</title>
          <description>Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4100" spread="13.9340"/>
                    <measurement group_id="O2" value="7.4600" spread="16.3510"/>
                    <measurement group_id="O3" value="3.9200" spread="12.6830"/>
                    <measurement group_id="O4" value="4.3400" spread="12.6430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment</title>
        <description>Percent change in TC = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment</title>
          <description>Percent change in TC = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.0000" spread="11.2080"/>
                    <measurement group_id="O2" value="-46.6300" spread="12.8180"/>
                    <measurement group_id="O3" value="-39.5600" spread="12.6640"/>
                    <measurement group_id="O4" value="-41.7100" spread="15.1500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment</title>
        <description>Percent change in TG = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment</title>
          <description>Percent change in TG = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.8500" spread="23.7090"/>
                    <measurement group_id="O2" value="-35.0000" spread="23.9710"/>
                    <measurement group_id="O3" value="-22.9500" spread="28.1390"/>
                    <measurement group_id="O4" value="-25.8200" spread="26.6190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment</title>
        <description>Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment</title>
          <description>Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.6500" spread="13.6770"/>
                    <measurement group_id="O2" value="-58.9100" spread="14.9320"/>
                    <measurement group_id="O3" value="-49.9300" spread="14.7380"/>
                    <measurement group_id="O4" value="-52.3700" spread="18.4290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment</title>
        <description>Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment</title>
          <description>Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.1100" spread="12.6280"/>
                    <measurement group_id="O2" value="-49.5000" spread="13.8210"/>
                    <measurement group_id="O3" value="-41.9500" spread="14.7500"/>
                    <measurement group_id="O4" value="-44.1700" spread="17.1790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment</title>
        <description>Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment</title>
          <description>Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8100" spread="13.0420"/>
                    <measurement group_id="O2" value="2.6800" spread="11.5020"/>
                    <measurement group_id="O3" value="1.4900" spread="9.6830"/>
                    <measurement group_id="O4" value="2.1300" spread="10.7410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in TC/HDL-C After 6 Weeks Combination Treatment</title>
        <description>Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in TC/HDL-C After 6 Weeks Combination Treatment</title>
          <description>Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.5200" spread="13.2280"/>
                    <measurement group_id="O2" value="-49.4600" spread="13.5750"/>
                    <measurement group_id="O3" value="-41.2700" spread="13.0210"/>
                    <measurement group_id="O4" value="-43.4500" spread="16.3430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment</title>
        <description>Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment</title>
          <description>Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.4700" spread="15.5470"/>
                    <measurement group_id="O2" value="-65.2500" spread="16.6800"/>
                    <measurement group_id="O3" value="-57.1300" spread="14.7770"/>
                    <measurement group_id="O4" value="-58.6600" spread="21.1300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment</title>
        <description>Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment</title>
          <description>Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.4200" spread="15.4150"/>
                    <measurement group_id="O2" value="-60.8900" spread="15.5030"/>
                    <measurement group_id="O3" value="-51.1100" spread="15.3800"/>
                    <measurement group_id="O4" value="-53.5100" spread="20.2230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment</title>
        <description>Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment</title>
          <description>Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.3900" spread="13.8690"/>
                    <measurement group_id="O2" value="-50.2400" spread="14.2570"/>
                    <measurement group_id="O3" value="-42.5400" spread="14.2480"/>
                    <measurement group_id="O4" value="-44.7600" spread="17.8420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment</title>
        <description>Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment</title>
          <description>Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.1200" spread="-99.0000" lower_limit="-99.0" upper_limit="20295.0"/>
                    <measurement group_id="O2" value="-9.5300" spread="-97.9000" lower_limit="-97.9" upper_limit="2368.3"/>
                    <measurement group_id="O3" value="15.0300" spread="-91.5000" lower_limit="-91.5" upper_limit="1611.4"/>
                    <measurement group_id="O4" value="0.4200" spread="-94.9000" lower_limit="-94.9" upper_limit="1270.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C After 6 Weeks Monotherapy</title>
        <description>Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value*100</description>
        <time_frame>Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R10 to R10 + E10</title>
            <description>Rosuvastatin 10 mg followed by Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O2">
            <title>R20 to R20 + E10</title>
            <description>Rosuvastatin 20 mg followed by Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O3">
            <title>S40 to S40 + E10</title>
            <description>Simvastatin 40 mg followed by Simvastatin 40 mg + Ezetimibe 10 mg</description>
          </group>
          <group group_id="O4">
            <title>S80 to S80 + E10</title>
            <description>Simvastatin 80 mg followed by Simvastatin 80 mg + Ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C After 6 Weeks Monotherapy</title>
          <description>Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.4900" spread="13.1080"/>
                    <measurement group_id="O2" value="-53.5900" spread="10.5030"/>
                    <measurement group_id="O3" value="-40.8600" spread="12.4130"/>
                    <measurement group_id="O4" value="-46.3500" spread="16.1880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin 10 mg</title>
          <description>Rosuvastatin 10 mg Monotherapy arm</description>
        </group>
        <group group_id="E2">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg Monotherapy arm</description>
        </group>
        <group group_id="E3">
          <title>Simvastatin 40 mg</title>
          <description>Simvastatin 40 mg Monotherapy arm</description>
        </group>
        <group group_id="E4">
          <title>Simvastatin 80 mg</title>
          <description>Simvastatin 80 mg Monotherapy arm</description>
        </group>
        <group group_id="E5">
          <title>Rosu 10 mg + Eze 10 mg</title>
          <description>Rosuvastatin 10 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="E6">
          <title>Rosu 20 mg + Eze 10 mg</title>
          <description>Rosuvastatin 20 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="E7">
          <title>Simva 40 mg + Eze 10 mg</title>
          <description>Simvastatin 40 mg + Ezetimibe 10 mg</description>
        </group>
        <group group_id="E8">
          <title>Simva 80 mg + Eze 10 mg</title>
          <description>Simvastatin 80 mg + Ezetimibe 10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="5"/>
                <counts group_id="E3" subjects_affected="1"/>
                <counts group_id="E4" subjects_affected="3"/>
                <counts group_id="E5" subjects_affected="4"/>
                <counts group_id="E6" subjects_affected="1"/>
                <counts group_id="E7" subjects_affected="7"/>
                <counts group_id="E8" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25"/>
                <counts group_id="E2" subjects_affected="31"/>
                <counts group_id="E3" subjects_affected="28"/>
                <counts group_id="E4" subjects_affected="26"/>
                <counts group_id="E5" subjects_affected="18"/>
                <counts group_id="E6" subjects_affected="23"/>
                <counts group_id="E7" subjects_affected="24"/>
                <counts group_id="E8" subjects_affected="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>AZTrial_Results_Posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

